Global Lung Cancer Diagnostic Test Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 4.07 billion by 2030 and is anticipated to register a CAGR of 7.50%. Lung cancer is a cancer that develops in the lungs. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLLC) are the two main forms of lung cancer, and they are treated differently (SCLC). According to the American Cancer Society, non-small cell lung cancer accounts for 80 percent to 85 percent of lung cancer cases, while small cell lung cancer accounts for 10% to 15% of cases. Oat cell lung cancer is another name for small cell lung cancer. Biomarkers, imaging tests, and biopsy are some of the most essential lung cancer screening techniques. Increased test approvals by regulatory bodies, investments in research, and strategic expansions by major players operating in the lung cancer diagnostic and screening market to strengthen their geographical footprint are among the major factors driving market growth during the forecast period (2021-2028). Tagrisso, for example, was recently approved by the US Food and Drug Administration as the first adjuvant treatment for patients with non-small cell lung cancer whose tumours carry a specific genetic mutation.
The increased focus on lung cancer diagnosis and screening test research and development is one of the major reasons driving market expansion. For example, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based technique in April 2020 that enables for the early detection of lung cancer via a simple urine test. The method detects biomarkers produced by peptide-coated nanoparticles interacting with disease-associated proteases in the tumour microenvironment. The urine test was shown to detect tumours as tiny as 2.8 mm in two separate animal models of lung cancer. The researchers anticipate that this type of noninvasive diagnosis will reduce the number of false positives associated with current test methods and aid in the early detection of more malignancies.
Download free sample copy of this report @
Key Highlights of Lung Cancer Diagnostic Test Market:
- Siemens Healthineers will launch Magnetom Free in November 2021. Star is a low-cost whole-body MRI scanner that aims to provide access to magnetic resonance imaging around the world.
- Agilent Technologies Inc. announced in October 2021 that its PD-L1 IHC 22C3 pharmDx assay has received European Union approval for use in Triple-Negative Breast Cancer (TNBC).
Key Market Insights from the report:
Global Lung Cancer Diagnostic Test Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 4.07 billion by 2030 and is anticipated to register a CAGR of 7.50%. The Global Lung Cancer Diagnostic Test Market is segmented by Test Type, Cancer Type, End-Use Industry and Region.
By Test Type:
Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others)
By Cancer Type:
Non-small cell lung cancer and Small Cell Lung Cancer
Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape & their strategies of Lung Cancer Diagnostic Test Market:
The key players operating in the Global Lung Cancer Diagnostic Test Market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
Ask for discount@
Global Lung Cancer Diagnostic Test Market, By Test Type:
- Biomarkers Test
- Imaging Test
Global Lung Cancer Diagnostic Test Market, By Cancer Type:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Global Lung Cancer Diagnostic Test Market, By End-User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Some Important Points Answered in this Market Report Are Given Below:
- Explains an overview of the product portfolio, including product development, planning, and positioning
- Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
- Detailed analysis of the market revenue over the forecasted period.
- Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
- Study on the segments that are anticipated to dominate the market.
- Study on the regional analysis that is expected to register the highest growth over the forecast period
Global Gastric Cancer Treatment Market, By Treatment (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2029
Global Biomarker Market, By Product (Consumables and Services), By Disease Indication (Cancer, Cardiovascular disorders and Others), By Application (Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Estimation
- Top-Down Approach
- Bottom-Up Approach
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Opportunities
- Market Trends
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
About Prophecy Market Insights
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.
Company Name: Prophecy Market Insights
Contact Person: Sidhant
Email: Send Email
Phone: +1 8605312701
Address:964 E. Badillo Street #2042 Covina, CA 91724
Country: United States